Plain-English translation of NCT06239636 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a very early safety study testing a new treatment called —genetically modified insulin-producing cells from a donor—transplanted directly into the forearm muscle. The goal is to see if this treatment can help your body produce its own insulin again without requiring you to take strong immune-suppressing drugs. Researchers will monitor you closely over one year with regular blood tests, scans, and glucose monitoring.
People with type 1 diabetes have lost the ability to produce their own insulin and must inject it multiple times daily for life. This treatment aims to restore that natural insulin production safely, potentially reducing the burden of daily insulin injections and the need for lifelong immunosuppressive medications that come with transplants.
You likely qualify if…
You likely don't qualify if…
You would receive a single transplant procedure where modified insulin-producing cells are injected into your forearm muscle. Over the following year, you would attend frequent follow-up visits for blood tests, physical exams, and MRI scans to monitor the transplant's safety and how well your body responds. You would continue tracking your blood sugar with glucose monitoring devices and work closely with your diabetes care team throughout the study.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Sweden